Risk of pulmonary embolism/venous thrombosis

Menopause

Volumn , Issue , 2007, Pages 491-500

  Westhoff, Carolyn ^a  

^a Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882830971     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369443-0/50044-2     Document Type: Chapter

References (64)

1. Ault M, Artal R Upper extremity DVT: What is the risk?. Arch Intern Med 1998, 158:1950-1951.
2. Anderson FA, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DT Study Arch Intern Med 1991, 151:933-938.
3. Quinn D, Thompson B, Terrin M, et al. A prospective investigation of pulmonary embolism in women and men. J Am Med Assoc 1992, 268:1689-1696.
4. Prandoni P, Lensing AW, Cogo AJ, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996, 125:1-7.
5. Baker W Diagnosis of deep vein thrombosis and pulmonary embolism. Curr Concepts Thromb 1998, 82:475-495.
6. Merli G Diagnostic assessment of deep venous thrombosis and pulmonary embolism. Am J Med 2005, 118:3S-12S.
7. Haas S Treatment of deep venous thrombosis and pulmonary embolism. Current recommendations. Curr Concepts Thromb 1998, 82:495-510.
8. Dexter L President's Address: The chair and venous thrombosis. Trans Am Clin Climatol Assoc 1973, 84:1-15.
9. 506 allele, and venous thrombosis. Ann Hematol 1996, 72:166-176.
10. Bertina R, Koeleman B, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature (London) 1994, 369:64-67.
11. Lowe GDO, Rumley A, Woodward M, Reid E End of the line for "third-generation"pill controversy?. Lancet 1996, 349:1113-1114.
12. Poort S, Rosendaal F, Reitsma P, Bertina R A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in ve. Blood 1996, 88:3698-3703.
13. Coon W, Willis P, Keller J Venous thromboembolism and other venous disease in the Tecumseh community health study. Circulation 1973, 47:839-846.
14. Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism. Arch Intern Med 1998, 158:585-593.
15. Nordstrom M, Lindblad B, Bergqvist D, Kjellstrom T A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992, 232:155-160.
16. Goldhaber S, Grodstein F, Stampfer M, et al. A prospective study of risk factors for pulmonary embolism in women. J Am Med Assoc 1997, 277:642-645.
17. Beyth R, Cohen A, Landefield C Long-term outcomes of deep-vein thrombosis. Arch Intern Med 1995, 155:1031-1037.
18. White R, Zhou H, Romano P Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann Intern Med 1998, 128:737-740.
19. Rosendaal F Risk factors for venous thrombosis: prevalence, risk, and interaction. Semin Hematol 1997, 34:171-187.
20. Tait RC, Walker ID, Reitsma PH, et al. Prevalence of protein C deficiency in the healthy population. Thromb Haemostasis 1995, 73:87-93.
21. Allaart C, Briet E Familial venous thrombophilia. Hemostasis and thrombosis 1994, 1349-1360. Churchill-Livingstone, New York. A. Bloom, C. Forbes, D. Thomas (Eds.).
22. Bovill EG, Bauer KA, Dickermann JD, Callas P, West B The clinical spectrum of heterozygous protein C deficiency in a large New England kindred. Blood 1989, 73:712-717.
23. Koster T, Rosendaal FR, Briet E, et al. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden thrombophilia study). Blood 1995, 85:2756-2761.
24. Beauchamp NJ, Dykes AC, Parikh N, Tait RC, Daly ME The prevalence of, and molecular defects underlying, inherited protein S deficiency in the general population. Br J Haemotology 2004, 125:647-654.
25. Hiejboer H, Brandjes DP, Buller HR, Sturk A, Ten Cate JW Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990, 323:1512-1516.
26. Dahlback B, Carlsson M, Svensson P Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofacto. Proc Natl Acad Sci USA 1993, 90:1004-1008.
27. Ridker PM, Hennekens CH, Lindpainter K, et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995, 332:912-917.
28. Vandenbroucke J, Heimerhorst F Risk of venous thrombosis with hormone-replacement therapy. Lancet 1996, 348:972.
29. Rosendaal FR, Doggen CJM, Zivelin A, et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 1998, 79:706-708.
30. THRIFT Consensus Group Risk of and prophylaxis for venous thromboembolism in hospital patients. Br Med J 1992, 305:567-574.
31. Clagett G, Reisch J Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann Surg 1988, 208:227-240.
32. Salzman E, Hirsch J The epidemiology, pathogenesis, and natural history of venous thrombosis. Hemostasis and thrombosis: basic principles and clinical practice 1994, 1275-1296. Lippincott, Philadelphia. R. Coleman, J. Hirsch, V. Marder, E. Salzman (Eds.).
33. Petitti D, Wingerd J, Pellegrin F, Ramcharan S Risk of vascular disease in women: smoking, oral contraceptives, noncontraceptive estrogens, and other factors. J Am Med Assoc 1979, 242:1150-1154.
34. Gutthann SP, Garcia Rodriguez LA, Castellsague J, Oliart AD Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. Br Med J 1997, 314:796-800.
35. Petitti D, Wingerd J, Pellegrin F, Ramcharan S Oral contraceptives, smoking, and other factors in relation to risk of venous thromboembolic disease. Am J Epidemiol 1978, 108:480-485.
36. Jick H, Jick S, Gurewich V, Myers MW, Vasilakis C Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestogen components. Lancet 1995, 346:1589-1592.
37. World Health Organization Collaborative Study of Cardiovascular Disease Steroid Hormone Contraception Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995, 346:1582-1588.
38. Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, MacRae KD Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Br Med J 1996, 312:83-88.
39. Inman WH, Vessey MP, Westerholm B, Engelund A Thromboembolism disease and the steroidal content of oral contraceptives: a report to the Committee on Safety of Drugs. Br Med J 1970, 2:203-209.
40. Gerstman BB, Piper JM, Tomita DK, et al. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991, 133:32-37.
41. Realini J, Goldzieher J Oral contraceptives and cardiovascular disease: a critique of the epidemiological studies. Am J Obstet Gynecol 1985, 152:729-798.
42. Lobo R Estrogen and the risk of coagulopathy. Am J Med 1992, 92:283-285.
43. Boston Collaborative Drug Surveillance Program Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to postmenopausal estrogen therapy. N Engl J Med 1974, 290:15-19.
44. Nachtigall L, Nachtigall R, Nachtigall R, Beckman E Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 1979, 54:74-79.
45. Devor M, Barred-Connor E, Renvall M, Feigal D, Ramsdell J Es-trogen replacement therapy and the risk of venous thrombosis. Am J Med 1992, 92:275-282.
46. Grodstein F, Stampfer M, Manson I, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996, 335:453-461.
47. Daly E, Vessey MP, Painter R, Hawkins M Case-control study of venous thromboembolism risk in users of hormone replacement therapy. Lancet 1996, 348:1027.
48. Jick H, Derby L, Myers M, Vasilakis C, Newton K Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996, 348:981-983.
49. Varas-Lorenzo C, Garcia-Rodriguez L, Cattaruzzi C, et al. Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: a population-based study in Southern Europe. Am J Epidemiol 1998, 147:387-390.
50. Daly E, Vessey MP, Hawkins MM, et al. Risk of venous thromboem-bolism in users of hormone replacement therapy. Lancet 1996, 348:977-980.
51. Scarabin P, Oger E, Plu-Bureau G Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003, 362:428-432. on behalf of the EStrogen and THromboEmbolism Risk (ESTHER) Study Group.
52. Douketis JD, Julian JA, Kearon C, et al. Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case-control study. J Thromb Haemostasis 2005, 3:943-948.
53. Smith NL, Heckbert SR, Lemaitre RN, et al. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. J Am MedAssoc 2004, 292:1581-1587.
54. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women. J Am MedAssoc 1998, 280:605-613.
55. Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/Progestin Replacement Study. Ann Intern Med 2000, 132:689-696. for the Heart and Estrogen/ Progestin Replacement Study Research Group.
56. Cushman M, Kuller LH, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. J Am MedAssoc 2004, 292:1573-1580. for the Women's Health Initiative Investigators.
57. Lidegaard O Thrombotic diseases in young women and the influence of oral contraceptives. Am J Obset Gynecol 1998, 179:S62-S67.
58. Grodstein F, Stampfer M, Goldhaber S, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996, 348:983-987.
59. Writing Group for the PEPI Trial Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women. J Am Med Assoc 1995, 273:199-208.
60. Hoibraaten E, Qyigstad E, Arnesen H, et al. Increased risk of recurrent venous thromboembolism during hormone replacement therapy. Thromb Haemostasis 2000, 84:961-967.
61. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989, 320:479-484.
62. Delmas P, Mitlak B, Christiaansen C Effects of raloxifene in post menopausal women (letter). N Engl J Med 1998, 338:1313-1314.
63. Eli Lilly Company Evista product information 1998, Eli Lilly and Company, Indianapolis, IN.
64. Douketis JD, Ginsberg JS, Holbrook A, et al. A reevaluation of the risk for venous thromboembolism with the use of oral contraceptives and hormone replacement therapy. Arch Intern Med 1997, 157:1522-1530.